In Vivo CRISPR Screens Uncover 2 Gene Targets to Boost T Cell Therapy in Solid Tumors
Updated
Updated · Nature.com · Aug 12
In Vivo CRISPR Screens Uncover 2 Gene Targets to Boost T Cell Therapy in Solid Tumors
2 articles · Updated · Nature.com · Aug 12
Summary
Genome-wide in vivo CRISPR screens in human T cells identified P2RY8 and GNAS as edits that improve performance against solid tumors, addressing limits of earlier in vitro screening approaches.
The mouse model enabled efficient recovery of human tumor-infiltrating T cells with dysfunction hallmarks, allowing researchers to separately screen for genes affecting tumor infiltration and effector function.
P2RY8 emerged as a brake on T-cell tumor entry through the P2RY8-Gα13 signaling axis, while GNAS drove intratumoral dysfunction via Gαs signaling downstream of multiple suppressive GPCR cues.
GNAS knockout made T cells resistant to several suppressive signals and improved efficacy across multiple preclinical solid-tumor models in both CAR and TCR systems.
Combinatorial P2RY8-GNAS knockout further strengthened tumor control, suggesting the platform could systematically find complementary edits for next-generation solid-tumor T-cell therapies.
Could editing just two genes finally unlock the power of T-cell therapies to completely eradicate stubborn solid tumors in humans?
What other crucial cancer-fighting genes have scientists missed because traditional lab cultures fail to mimic the true tumor microenvironment?
Will silencing the immune system's natural brakes to destroy solid tumors trigger dangerous autoimmune side effects once tested in human trials?
Unlocking Solid Tumor Immunotherapy: How In Vivo CRISPR Screens and Multiplex Editing Are Redefining CAR-T and TCR-T Therapies (2025–2026)
Overview
Recent breakthroughs in cancer immunotherapy have come from moving genetic screens out of the lab dish and into living tumor models. Traditional in vitro tests missed key barriers, but new in vivo CRISPR screens revealed how solid tumors block and exhaust T cells. By knocking out genes like P2RY8 and GNAS, scientists enabled T cells to enter tumors and survive harsh conditions, leading to dramatic tumor clearance in animal models. These advances, combined with safer gene editing tools and improved manufacturing methods, are now driving the next generation of powerful, multi-edited cell therapies toward clinical trials and broader patient access.